Fig. 8
From: Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis
Very low–density lipoprotein and low-density lipoprotein as key biomarkers of fibrosis/cirrhosis in humans. A Significant metabolites identified through the differential gene expression analysis of a retrospective cohort of patients with fibrosis/cirrhosis. Log2 fold changes were calculated by comparing the FIB4 scores of patients with advanced disease (F3 or F4) with those of patients with no or mild fibrosis (F0–F2). Significant metabolites associated with cirrhosis. Log2 fold changes were determined by comparing patients with cirrhosis with those without cirrhosis. B Changes in lipoproteins during the progression of MASH/fibrosis in mice